Soligenix disclosed that it has commenced the enrollment of patients for its Phase 2 trial (protocol number DUS-AUBD-01) investigating SGX945 (dusquetide).

Enlonstobart, a groundbreaking therapeutic agent, is a fully humanized monoclonal antibody developed by Hangzhou Shangjian Biotechnology Co., Ltd.

Merck obtains exclusive global rights for LM-299, a clinical investigational bispecific antibody targeting PD-1 and VEGF, from LaNova Medicines Ltd.

Sotorasib is an oral medication developed to target a specific mutation in the KRAS gene, known as KRAS G12C, which is implicated in various cancers.

Tune Therapeutics Enters Clinical Arena with TUNE-401: A Novel Epigenetic Silencer Targeting Hepatitis B.

Disitamab Vedotin is an antibody-drug conjugate (ADC) developed by Hengrui Medicine, targeting human epidermal growth factor receptor 2 (HER2).

Tirzepatide treatment in obese or overweight adults with pre-diabetes led to lasting weight reduction, with almost 99% staying free of diabetes after 176 weeks.

PLX-4545 is a molecular glue drug developed by Plexium, Inc. The drug targets IKZF2 and is intended for the treatment of neoplasms.

MoonLake Immunotherapeutics has launched Phase 3 of the IZAR program for the Nanobody® sonelokimab in individuals suffering from active psoriatic arthritis.

Mipomersen, developed by Isis Pharmaceuticals and marketed by Genzyme, is an antisense oligonucleotide that targets the apolipoprotein B-100 (ApoB-100) mRNA.

Gan & Lee Pharmaceuticals reported favorable Phase 1 outcomes for its oral GLP-1 receptor agonist, GZR18 tablet, in healthy subjects, showing a weight loss of 4.16% over two weeks.

Omaveloxolone is a small molecule drug developed by Reata Pharmaceuticals, Inc. that targets the Nrf2 protein.